For research use only. Not for therapeutic Use.
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].
| Catalog Number | I040850 |
| CAS Number | 2445259-99-2 |
| Purity | ≥95% |
| Reference | [1]. Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12. [2]. Reozalimab. IMGT/mAb-DB. |
